


Peripheral signature of altered synaptic integrity in young onset Cannabis Use Disorder: A pilot proteomic study of circulating extracellular vesicles Suhas Ganesh^{*1,6}, TuKiet T. Lam^{2,3}, Angus Clark Nairn¹, Rolando Garcia-Milian⁴, Erez Eitan⁵, Mohini Ranganathan^{*1}

1. Department of Psychiatry, 2. Department of Molecular Biophysics and Biochemistry, 3. Keck Mass Spectrometry & Proteomics Resource, 4. Bioinformatics Support Program, Harvey Cushing/John Hay Whitney Medical Library, 1-4: Yale University School of Medicine, New Haven, CT, US; 5. NeuroDex, Inc., 27 Strathmore Rd, Natick, MA; 6. Central Institute of Psychiatry, Ranchi, India

Introduction

- Cannabis use often begins in adolescence or early \bullet adulthood - critical periods of neurodevelopment and neuromaturation
- ~30% of cannabis users may develop Cannabis Use \bullet Disorder (CUD)
- Chronic cannabis exposure results in neuropsychiatric and cognitive consequences
- Challenges in obtaining brain tissues from young persons with CUD – limits the study of molecular neuropathology Neuron Derived Extracellular vesicles (NDEs), assayed from the periphery may reveal markers of neuropathology in CUD



Proteomic studies of NDEs cargo may provide some insights into molecular signatures of cellular milieu

Aims


- To compare the proteomic profile of plasma derived NDEs in young onset CUD and matched healthy controls
- 2. To examine the enrichment of differentially abundant proteins to genes relevant to synaptic function

Methods

- Sample: 10 young-onset CUD and 10 age and gender matched Healthy Controls (HCs)
- Cannabis exposure characterized by Scale for \bullet Assessment of Lifetime Assessment of Cannabis Use
- NDEs enriched from plasma Extracellular Vesicle (EV) pool using ExoSORT (Figure 1A). NDE morphology and abundance characterized with electron microscopy and Nanoparticle Tracking Analysis (Figure 1B, 1C) • Label Free Quantification (LFQ) analysis of NDE proteome with Liquid Chromatography, Tandem Mass Spectrometry (LC-MS/MS)

©NeuroDex 2022

Figure 2: Differentially abundant NDE proteins between CUD and matched controls



Protein identity examined in Mascot search engine \bullet

LFQ data processed in Progenesis QI software to derive differential abundance between CUD and HC

Enrichment and pathway analysis with Panther and Ingenuity Pathway Analysis


Results

- Total of 231 (+/-10) unique proteins were identified in NDE preparations in 20 samples
- 28 proteins differentially abundant between CUD and controls
- Difference in properdin (CFP) statistically significant after correction (Figure 2)
- Nominally significant proteins included SHANK1 a synaptic protein and proteins in complement and coagulation cascade (Figure 3)

Discussion

Reduced abundance of SHANK1 in CUD - protein involved in the structural and functional integrity of glutamatergic post-synapse

Figure 3: Top four differentially regulated proteins



- Differential abundance of proteins in complement, coagulation and immune cascades possible role of neuroimmune axis in chronic cannabis exposure
- LFQ analysis of NDEs from plasma potential insights into neuropathology of CUD and other \bullet neurodevelopmental disorders
- Results warrant validation in future studies in larger samples

References

- 1. Mustapic M, Eitan E, Werner JK, Jr., Berkowitz ST, Lazaropoulos MP, Tran J, et al. (2017): Plasma Extracellular Vesicles Enriched for Neuronal Origin: A Potential Window into Brain Pathologic Processes. Front Neurosci. 11:278.
- 2. Monteiro P, Feng G (2017): SHANK proteins: roles at the synapse and in autism spectrum disorder. Nat Rev Neurosci. 18:147-157.
- 3. Bara A, Ferland JN, Rompala G, Szutorisz H, Hurd YL (2021): Cannabis and synaptic reprogramming of the developing brain. Nat Rev Neurosci. 22:423-438.

Acknowledgements: The work was supported by a pilot award by the Yale-NIDA Neuroporteomic center (DA018343) to SG and MR and a NARSAD young investigator award #27340 by Brain and Behavior Research Foundation to SG. We acknowledge the staff of the Schizophrenia Neuropharmacology Research Group at Yale (SNRGY) for clinical data collection, Keck Mass Spectrometry and Proteomic Resource for MS data acquisition and analysis; Neurodex INC for EV preparation.